Prostate Fusion Biopsy

Prostate Fusion Biopsy

Prostate Fusion Biopsy

A prostate biopsy is a procedure to remove samples of tissue from the prostate and the only definitive way to diagnose prostate cancer. Although the transrectal ultrasound guided 10-12 core systematic biopsy is the current standard procedure, the sensitivity of the method is limited. Autopsy series compared with the prostate biopsy show that the sensitivity of conventional prostate biopsy is at 53%. Because of this diagnostic uncertainty, approximately one-third of patients with ongoing cancer suspicion must undergo a repeat biopsy within five years after the initial biopsy, which in turn gives a cancer diagnosis in 13% to 41% of cases. This normally leads to taking more biopsy sampling and increase in the detection of clinically insignificant prostate cancer with the risk of unnecessary treatment. Recent developments suggest that magnetic resonance imaging (MRI), performed on a 3 Tesla scanner, has the ability to improve the detection and the risk classification of prostate cancer. In advanced medical centers, targeted biopsy techniques of suspected cancer lesions detected by MP-MRI appears to be preferred. These techniques allowed the diagnosis of low-grade tumours.

With the help of high resolution 3 Tesla Multiparametric MRI is taken before biopsy and the suspicious areas are detected prostate fusion biopsy, and transferred to a special ultrasound device (fusion biopsy device). In other words, prostate biopsy (fusion biopsy) is the latest prostate cancer diagnostic method that minimizes the possibility of prostate cancer overlook and is applied in a few centers in our country.

With the aid of high resolution 3 Tesla Multiparametric MRI, the foci suspicious of cancer in prostate are marked prior to biopsy and images are transferred to a special ultrasound device (fusion biopsy device) enabling to take samples from MR-identified targets in addition to the standard 12-14 core biopsies. In other words, prostate biopsy (fusion biopsy) is the latest prostate cancer diagnostic method that minimizes the possibility of missing prostate cancer lesions and is applied in a few centers in our country.

3 Tesla multiparametric magnetic resonance imaging-transrectal ultrasound (MRI-TRUS)- fusion (CF) targeted biopsy is a method of detecting suspicious foci within the prostate and providing biopsy with increased level of sensitivity by means of advanced technology device and software. With this method, cancer foci can be detected with superior diagnostic accuracy and unnecessary biopsies are reduced.